key: cord-0856009-lurly2y2
authors: Alam, Muhammad Tanveer; Mehdi, Asad; Timsaal, Yumna; Rehan, Muhammad; Kumar, Arjun; Shaikh, Imran Sarwar; Yasmin, Farah; Memon, Gul Muhammad; Ahmed, Nisar; Asghar, Muhammad Sohaib
title: The clinical course, biochemical markers, and clinical outcomes of COVID-19 positive patients from the third wave in Pakistan: A retrospective cohort study
date: 2022-04-19
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2022.103599
sha: 6c56737e934853c56c930372a0372c013696a1e0
doc_id: 856009
cord_uid: lurly2y2

BACKGROUND: Third wave of COVID-19 has affected several countries. Case fatality rates from first and second waves are expected to be surpassed by the current wave due to various variant transmissions. This study was aimed to compare and contrast the significant clinical markers between survivors and non-survivors during the third wave of COVID-19 to assess severity and prognosis. METHODS: It includes all the patients who were diagnosed with COVID-19 polymerase chain reaction (PCR) during the third wave, and were monitored for their disease course and outcomes. A total of 209 patients were included in the analysis via non-probability consecutive sampling method. RESULTS: The median age was higher in non-surviving patients (p = 0.010). Majority of deaths occurred in intensive care patients (p < 0.001) and those with diabetes (p = 0.032) and hypertension (p = 0.003). Fever was the most predominant symptom in all patients (78.9%), dyspnea was common among expired individuals (p = 0.043) while recovered patients were more likely to be asymptomatic (p = 0.044). Gastrointestinal symptoms were not found marked during this wave. Being on ventilator has higher mortality (p < 0.001). Predominant radiological findings were interstitial patches or infiltrate (43.7%). Multivariable analysis showed hypertension (p = 0.042), BiPAP/CPAP (p < 0.001), being on ventilator (p = 0.004), and ARDS (p < 0.001) was associated with poor survival while patchy interstitial infiltrates on X-ray had good survival probability (p = 0.032). On Kaplan-Meier survival analysis, hypertension (p = 0.003), BiPAP/CPAP (p = 0.008), ventilator (p = 0.025), ICU stay (p = 0.001), high-grade fever (p = 0.001), and ARDS (p < 0.001) had reduced cumulative survival. CONCLUSION: Certain biochemical markers were more predictive of disease severity in the third-wave than the preceding waves.

The coronavirus disease 2019 caused by the severe acute respiratory syndrome 29 coronavirus 2 (SARS-CoV-2) that originated in Wuhan, Hubei Province has been a major cause 30 of global public health concern [1]. It has affected approximately 264 million lives worldwide, 31 as of December, 2021 inclusive of five million deaths, with the virus having an estimated 32 reproductive number of 2.87 (95%CI: 2.39-3.44) [2] . Due to its multifaceted clinical prognosis, 33 insidious onset and non-specific disease course, COVID-19 patients continue to receive 34 delayed care as a result of which the development of acute respiratory distress syndrome 35 (ARDS) has been reported, severe enough to require respiratory support [3] . 33% of infected 36 patients are found to have asymptomatic illness while those who present with symptoms can 37 range from mild to critical, with a higher frequency of mild disease state [4, 5] . The case fatality 38 rate shows an increase from <0.6% to 2.2% for patients over 60 years old and rises to over 39 9.3% at age 80, proving to be highly age dependent [6] . After surviving the first and second 40 wave of COVID-19, the third wave hit various countries like Spain in early 2021 exhibiting 41 various differential features such as greater number of reinfections and household contacts, a 42 highly transmissible B.1.1.7 strain, less severe cases, and lower mortality rates [7, 8] . A study 43 done in Japan showed that the most common underlying comorbidities reported during the third 44 wave were diabetes, hypertension, and pre-existing pulmonary disease [9] . Inflammatory 45 biomarkers also played a key role as for every 1 mg/dL rise in C-reactive protein (CRP), 10 46 IU/L rise in lactate dehydrogenase (LDH), and 100 ng/mL rise in ferritin, the risk for moderate 47 to severe disease was seen to surge by approximately 18%, 13%, and 9%, respectively [9] . 48

As the positivity rate in Pakistan surged to >10%, the country witnessed its third wave of 49 COVID-19 in March, 2021 [10] . The third wave hit Pakistan in the spring season similar to the 50 first wave, indicating the possibility of pollen to enhance disease transmission [11] . This study 51 was aimed to compare and contrast the significant clinical markers between survivors and non-52 survivors during the third wave of COVID-19 in Karachi, Pakistan to assess severity and 53 prognosis. 54

It was conducted in a single-center, retrospectively designed observational study, during the 56 months of March till May 2021, when the third wave was at peak in the region. The center 57 serves as one of largest facility for COVID-19 isolation and intensive care in the city of 58

Karachi. The study includes all the patients who were diagnosed with COVID-19 polymerase 59 chain reaction (PCR) positive via either nasopharyngeal or oropharyngeal swab. The diagnostic 60 kit exploits the principle of real-time fluorescence (RT-PCR) with USA-WA1/2020 stock 61 concentration 2.8E+05 TCID50/mL and a lower detection limit of 0.003 TCID50/mL. The 62 patients were monitored for their disease course and outcomes. A total of 209 patients were 63 included in the analysis, out of which one-third were in intensive care unit (ICU), and 60 64 patients died during the hospital stay (28.7%). The exclusion criteria were patients ongoing 65 treatment within the hospital at the time study recruitment (n=28), patients with incomplete 66 J o u r n a l P r e -p r o o f data on chart review (n=47), and those who were discharged early for home isolation without 67 complete recovery since no follow-up was available for them in chart review (n=61). 68

The manuscript conformed to STROCCS guidelines for reporting cohort studies [12] . The 69 research protocol was registered with registry board of Dow University Hospital (UIN# 70 IRB/DUH/2021/053). Owing to retrospective data collection, informed consent was waived. 71

The statistical analysis was conducted by the Statistical Package for the Social Sciences (SPSS 72 version 25.0, IBM Corp., Armonk, NY). Descriptive variables were presented as median and 73 interquartile range and were then compared using both non-parametric Mann-Whitney U-test. 74

The comparison of categorical data (presented as frequency and percentage) was performed 75 either using the Chi-square test or Fisher's exact test as appropriately indicated. A p-value of 76 <0.05 was considered statistically significant (2-tailed) . A receiver operating characteristic 77 (ROC) analysis was also obtained to determine the predictive laboratory parameters for 78 outcome as death. For categorical variables, univariate and multivariate regression was 79 performed to associate their outcome as death. Kaplan-Meier survival curves were illustrated 80 to demonstrate the survival logs among the study variables and cumulative survival of the study 81 subjects. 82

The median age was higher in non-surviving patients (p=0.010), with no gender discrimination 84 (p=0.793). Time since diagnosis (p=0.036) and time spent in hospital (p=0.005) were both 85 shorter in non-surviving patients. Majority of deaths occurred in intensive care patients 86 (p<0.001) and those with diabetes (p=0.032) and hypertension (p=0.003) as shown in Table 1 . 87

Fever was the most predominant symptom in all the patients (78.9%) as well as in expired 88 patients (p=0.035). Dyspnea was also found common among expired individuals (p=0.043) 89 while recovered patients were more likely to be asymptomatic (p=0.044). With increasing grade of fever, the risk of mortality increases (p<0.001). Such as >103 0 F temperature has a 91 mortality rate up to 56% as opposed to 28% in 101-103 0 F and 20% in <100 0 F. Gastrointestinal 92 symptoms were not found marked during this wave. Being on ventilator or use of BiPAP/CPAP 93 has higher mortality (p<0.001) as opposed to increased recovery with oxygen mask (p<0.001) 94 and nasal canula (p=0.009). Predominant radiological findings were interstitial patches or 95 infiltrate (43.7%) but with good recovery rate (p=0.001) in contrast to worse outcomes with 96 ARDS (p<0.001) as shown in Table 2 . 97

All vital markers were extreme in non-surviving group except pulse rate (p=0.089). Higher 98 TLC (p<0.001), neutrophils (p=0.008), MCV (p=0.008) and APTT (p=0.007) were noticed in 99 non-survivors among the hematological indices along with lower lymphocytes (p=0.004). 100

Deranged urea (p<0.001), creatinine (p<0.001), chloride (p=0.036), potassium (p=0.032), 101 bicarbonate (p<0.001), and magnesium (p=0.020) were found significant among renal profile 102 and electrolytes panel. All the inflammatory biomarkers including CRP, ferritin, LDH, 103 procalcitonin and D-dimer were markedly increased in non-survived patients (p<0.001), while 104 liver function enzymes were not discriminative among either group as shown in Table 3 . 105

Multivariable analysis showed Hypertension (p=0.042), BiPAP/CPAP (p<0.001), being on 106 ventilator (p=0.004), and ARDS (p<0.001) would be associated with poor survival while 107 patchy interstitial infiltrates on X-ray has good survival probability (p=0.032) as shown in 108 Table 4 . BiPAP/CPAP (p=0.008), ventilator (p=0.025), ICU stay (p=0.001), high-grade fever 116 (p=0.001), and ARDS (p<0.001) was associated with reduced cumulative survival as shown in 117 Figure 2 . 118

The present study, to the best of our knowledge, is the first report comparing clinical 120 characteristics between survivors and non-survivors during the course of the third wave of the 121 COVID-19 pandemic in Karachi, Pakistan. In this retrospective single-center study done in 122

Karachi, we describe subsequent risk factors and variables to highlight the contrast in adverse 123 outcomes of the surviving and non-surviving patients from March till May 2021. Our study 124 concluded to have a higher age but no gender discrimination in the non-surviving group. The 125 median age was 56 years in the recovered group and 60 years in the expired group. Previous 126 surveys undertaken to assess disease severity showed advanced age to be a strong predictor for 127 marked clinical deterioration due to the association of several comorbidities [13] [14] [15] [16] . A study 128 done by Zhang et al in Wuhan, China showed 50.7% of the participants to be males, further 129 establishing no gender inclination linked to adverse disease outcome [17] . 130

The most common complaints on admission were fever, cough and dyspnea. Nearly 78.9% of 131 patients in our study predominantly reported fever at the onset of symptomatic illness making 132 fever grading >103 o F an important prognostic factor between the surviving and non-surviving 133 group. Wang, Dawei et al. also identified that the most prevalent symptoms in the emergency 134 department (ED) for COVID cases were fever, dry cough, and dyspnea at 98.6%, 59.4% and 135 31.2%, respectively [18] . As suggested by another multicenter case series, only 43.8% of 136 patients reported fever at the onset, while 87.9% reported having had a fever during the course 137 of their hospitalization [19] . A retrospective cohort study identified an association between hyperthermia and mortality rate where mortality was seen to be lower (41%) in COVID patients 139 that recorded a temperature of less than 102°F compared to a higher mortality rate of nearly 140 70.6% and 100% in patients who had peak temperatures greater than 104°F and 105°F, 141 respectively [20] . Identifying mortality predictors such as body temperature gives us a chance 142 to better understand and manage adverse disease outcomes since there are certain predictors 143 such as age and gender that cannot be controlled. However, it remains disputed in literature 144 whether normothermia should be achieved in febrile intensive care unit (ICU) patients since 145 hyperthermia boosts the immune response to evade further pathogen invasion [21, 22] . 146

We noticed that comorbidities such as diabetes, hypertension, and chronic pulmonary disease 147 were prevalent amongst patients and resulted in a greater mortality rate. There are several 148 factors that link these chronic conditions and poor prognosis of patients with COVID-19. For 149 example, diabetes contributes towards patients becoming immunocompromised which puts 150 them at a greater risk of infectivity and a slower rate of recovery, posing a higher risk of 151 developing respiratory complications in the ICU during their hospital stay [23] . A meta-152 analysis that included 16,000 patients reported a significant association between mortality from 153 COVID-19 and diabetes. The disease was found to be two times more severe in diabetic 154 patients and diabetic patients were also two times more likely to expire from the infection; odds 155 ratio (OR) = 1.97. These patients required invasive ventilation and also had a greater likelihood 156 of developing ARDS [24, 25] . To establish diabetes as a sole determinant of adverse outcomes 157 in COVID-19 patients, a study was done in China that aimed to contrast clinical characteristics 158 between diabetic and non-diabetic COVID-19 infected patients. Researchers found that those 159 patients who only reported diabetes, in the absence of other comorbidities, were observed to 160 be at a higher risk of experiencing severe pulmonary complications such as pneumonia. The 161 prevalence of diabetes is responsible for initiating an uncontrolled inflammatory response, 162 resulting in hypercoagulability and releasing enzymes from injured tissue. They also found 163 J o u r n a l P r e -p r o o f various inflammatory serum biomarkers to be high in these patients such as CRP, 164 ferritin, . A rise in the aforementioned serum markers causes an inflammatory 165 storm in diabetic patients which plays an influential role in aggravating COVID symptoms 166 [9, 24, 26] . 167

Another comorbid found in our study that played an impactful role in mortality from COVID-168 19 was hypertension. Nearly half the patients were hypertensive and 38% of hypertensive 169 patients expired due to COVID complications. A survey found that hypertension could be 2. an intriguing conclusion drawn from several studies indicates that consumption of 177 antihypertensive agents like ACE inhibitors and angiotensin receptor blockers could lead to a 178 greater number of ACE2 receptors being expressed on the cell surface. Due to higher 179 expressivity of ACE2 receptors, a larger quantity of these receptors are also available for 180 SARS-CoV-2 to attach and subsequently infect the cells [23, 27, 29, 30] . Discontinuation of 181 antihypertensive agents is not advised in such individuals because these drugs often offer renal 182 and cardiovascular protection that might be crucial for ICU support in COVID-19 patients. Due 183 to minimal clinical evidence, there is a lack of sufficient literature supporting the benefit of 184 suspending antihypertensive drugs in these patients [29] . Moreover, studies show that ACE2 185 receptors protect the lungs from developing ARDS so the benefits could outweigh the harm 186 [31] . 187

There are certain limitations to this study, amongst which the most prominent factors are a 188 small cohort and single-center design. Owing to missing data for a substantial number of 189 patients, that were excluded from the study might have led to selection bias. However, the study 190 was able to associate many clinical and laboratory parameters with mortality. 

Predicting disease severity and outcome in 242

COVID-19 patients: A review of multiple biomarkers

Early predictors of clinical outcomes 245 of COVID-19 outbreak in

Trend towards reduction in COVID-19 in-hospital 247 mortality

Clinical characteristics of 140 patients infected with

SEN: sensitivity; SPE: specificity; C.I: confidence interval

Youden's index; PPV: positive predictive value, NPV: negative predictive value, AUC: area under curve, S.E: standard error of mean, ROC: receiver operating characteristic; MCV: mean corpuscular volume

APTT: activated partial thromboplastin time; INR: international normalized ratio; ALT: alanine aminotransferase; AST: aspartate aminotransferase; γGT: gamma glutamyl transferase; ALP: alkaline phosphatase; CRP: c-reactive protein; LDH: lactate the registry

Unique Identifying number or registration

Hyperlink to your specific registration

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.

Please state any sources of funding for your research All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Consent to participate was not required due to retrospective nature of the study.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors. 

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.